Eye Diseases
Conditions
Interventions
Superior nasal quadrant injection of 1.25 mg in 0.05ml Intravitreal Bevacizumab injection
Intravitreal Bevacizumab injection at the Superior Temporal quadrant of ocular surface
Intravitreal Bevacizumab injection at the Inferior temporal quadrant of the ocular surface
Intravitreal Bevacizumab injection at the Inferior nasal quadrant of the ocular surface
Sponsors
Alex Kweku Addo
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria: 1. The patient must be more than 18 years old. 2. The patient must have their diagnosis confirmed by a specialist or consultant Ophthalmologist. 3. The patient must have been scheduled to receive IVI of Bevacizumab
Exclusion criteria
Exclusion criteria: Exclusion Criteria 1. A patient who has had any previous intravitreal injections. 2. A patient with a pre-procedure IOP of > 21 mmHg. 3. A patient on systemic pain analgesics or topical analgesics or sedatives. 4. A patient on topical IOP lowering drugs. 5. A patient with a history of herpetic ocular infection. 6. A patient with an anterior segment condition that could affect pain sensation, such as conjunctival irritation, active conjunctivitis or keratitis or bullous keratopathy. 7. A patient who cannot see the VAS with the contralateral eye. 8. A patient who does not understand how to use the VAS.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The association between the pain score and the site of injection of Bevacizumab. | — |
Secondary
| Measure | Time frame |
|---|---|
| The self-reported pain scores after IVI of Bevacizumab. ;Factors associated with self-reported pain after IVI of Bevacizumab. ;IOP variations after IVI of Bevacizumab. ;Association between the reported pain and the intraocular pressure change after IVI of Bevacizumab | — |
Countries
Ghana
Contacts
Public ContactAlex Kweku Addo
Specialist Ophthalmologist at Korle BU teaching Hospital
Outcome results
None listed